Skip to main content

Together we are beating cancer

Donate now

Kat Arney

Kat joined Cancer Research UK in 2004, after spending six years as a laboratory researcher. Kat loves talking about science, and regularly comments in the media on the latest discoveries as well as giving talks to staff and supporters. She has since left Cancer Research UK to pursue a career as a freelance journalist and science writer.
Showing 12 out of 289 results
  • Science & Technology

Science Snaps: divide by two

We home in on tiny cellular structures called 'centrosomes', exploring new research on cancer cell division with implications for drug development. We home in on tiny cellular structures called 'centrosomes', exploring new research on cancer cell division with implications for drug development.

by Kat Arney | Analysis | 22 June 2015

22 June 2015

This entry is part 12 of 30 in the series Science Snaps
Hoax email

Hoax emails about cancer risks and treatments are misleading and confusing, so don't pass them on. Here are the facts behind the claims. Hoax emails about cancer risks and treatments are misleading and confusing, so don't pass them on. Here are the facts behind the claims.

by Kat Arney | Analysis | 8 May 2015

8 May 2015

Cannabis tincture

We have become aware that scammers are tricking cancer patients and their families into handing over money for ‘cannabis oil’, yet receiving nothing in return. We have become aware that scammers are tricking cancer patients and their families into handing over money for ‘cannabis oil’, yet receiving nothing in return.

by Kat Arney | Analysis | 20 April 2015

20 April 2015

This entry is part 10 of 30 in the series Science Snaps
Patchwork quilt
  • Health & Medicine
  • Science & Technology

Unpicking the genetic ‘patchwork’ in ovarian cancer

Our researchers are investigating the genetic 'patchwork' underlying ovarian tumours, which will lead to more effective treatments in the future. Our researchers are investigating the genetic 'patchwork' underlying ovarian tumours, which will lead to more effective treatments in the future.

by Kat Arney | Analysis | 12 March 2015

12 March 2015

Paper DNA

A Lethal Weapon against cancer? Researchers are using ‘synthetic lethality’ to develop new treatments based on targeting DNA repair processes. A Lethal Weapon against cancer? Researchers are using ‘synthetic lethality’ to develop new treatments based on targeting DNA repair processes.

by Kat Arney | Analysis | 24 February 2015

24 February 2015

  • Health & Medicine
  • Science & Technology

The Enemy Within – 50 years of fighting cancer

We look back on the last 50 years of cancer research, where we were, what we've achieved and what's still left to do. We look back on the last 50 years of cancer research, where we were, what we've achieved and what's still left to do.

by Kat Arney | Analysis | 25 December 2014

25 December 2014

PARP and inhibitor

Olaparib is the first PARP inhibitor to move closer to licensing in Europe. What is it, how does it work, and when will it be available in the UK? Olaparib is the first PARP inhibitor to move closer to licensing in Europe. What is it, how does it work, and when will it be available in the UK?

by Kat Arney | Analysis | 24 October 2014

24 October 2014

Paul Nurse and Tim Hunt

In 2001, our researchers Tim Hunt and Paul Nurse won a share of the Nobel prize for physiology or medicine. We look back at their achievements. In 2001, our researchers Tim Hunt and Paul Nurse won a share of the Nobel prize for physiology or medicine. We look back at their achievements.

by Kat Arney | Analysis | 6 October 2014

6 October 2014

This entry is part 19 of 30 in the series Our milestones

We speak to our pancreatic cancer expert Professor Andrew Biankin about how he's trying to change the picture for people with the disease. We speak to our pancreatic cancer expert Professor Andrew Biankin about how he's trying to change the picture for people with the disease.

by Kat Arney | Analysis | 10 September 2014

10 September 2014

Bob Marley at a concert

Our researchers in Manchester are using the power of DNA technology to study the genetic faults in the rare type of melanoma that killed Bob Marley. Our researchers in Manchester are using the power of DNA technology to study the genetic faults in the rare type of melanoma that killed Bob Marley.

by Kat Arney | Analysis | 20 August 2014

20 August 2014